oral semaglutide cardiovascular outcomes soul trial results 2024 2025 PDF) Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized soul trial oral semaglutide cardiovascular

Worth a watch and Id love to hear where others land on this

Cell 160 , 88104 (2015)

Because these are powerful medications, they are strictly FDA-approved for chronic weight management in specific populations

Similarly, there are reports of patients with psoriasis and metabolic syndrome being treated with GLP-1 receptor agonists in clinical practice, with some suggesting potential improvements in inflammatory markers, though causality cannot be established from these observations

The body needs time to adapt to GLP-1 receptor activation, and rushing this process creates unnecessary complications

Wegovy is designed to treat obesity in children and adults and is also used to treat adults who want to lose weight